Kytopen
Kytopen develops non-viral gene delivery systems that accelerate the discovery and manufacturing of cell and gene therapies. The company's proprietary Flowfect technology combines continuous fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP to billions of cells in minutes, enabling high-efficiency cell engineering. Kytopen offers two platforms: Flowfect Discover, an automated…
Funding snapshot
About
Kytopen develops non-viral gene delivery systems that accelerate the discovery and manufacturing of cell and gene therapies. The company's proprietary Flowfect technology combines continuous fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP to billions of cells in minutes, enabling high-efficiency cell engineering. Kytopen offers two platforms: Flowfect Discover, an automated high-throughput liquid-handling platform capable of running up to 96 transfection conditions in approximately 10 minutes for drug discovery and process optimization, and Flowfect TX, a closed-system instrument for large-scale payload delivery to billions of cells with predictive scaling from small-volume experiments to manufacturing. The technology eliminates the gene delivery bottleneck at the discovery stage, reducing costs and time to scale. Founded in 2017 and headquartered in Cambridge, Massachusetts, Kytopen has raised $44.5M in Series B funding from investors including Horizons Ventures, Engine Ventures, Northpond Ventures, MassVentures, and Telegraph Hill Partners.
Business model
Genomics > Enabling Technologies > Technology Platforms > Gene Editing
Team background
College Wise > Stanford University
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.